Sequoia Biotech Consulting’s Post

It's not too late to register for tomorrow's webinar, Commercialization as 'Plan A': Innovator Biotechs Must Define and Own their Commercial Strategy, Beginning Early. Bob Rambo, Bruce Seeley, Jeffrey Wade, and Robert Vieira will discuss their experiences navigating the complex realm of first asset commercialization in crowded markets and examine strategies that garner attention from investors, payers and strategic partners. Ed Saltzman and Alyssa Trigger will moderate this discussion which will also explore key success factors and learnings during the clinical development stage, the cultivation of favorable market conditions, and the characteristics of a truly viable product from a commercial standpoint. Don't miss it. Register at #Commercialization #AssetCommercialization #ClinicalDevelopment #CommercialDevelopment #Biotech

📊 Pharma-Biotech Product & Company Valuation: Learn the principles in just 1 day! Valuation is a complex and subjective task, especially in the life science industry. With high R&D attrition rates, long investment cycles, and intricate technologies, it's crucial to master this skill. 💡 Join CELforPharma's course led by Dr. Patrik Frei, Europe’s top life science valuation expert. In just 1️⃣ day, you will: * Learn the key aspects and most commonly used models in valuation * Get an excellent overview * Immediately apply your learnings in a practical business case 📅 Don’t miss out on this opportunity to enhance your valuation skills! #pharma #biotech #businessdevelopment #valuations Venture Valuation AG --- ❓ Would you like to know more about this course? 💬 Like the post & write YES in the comments and I’ll send you the course brochure!

A shout-out to all the biotech consultants out there! As decision makers, you may have heard the objection that consultants lack ownership of the issue. But let me tell you, I have worked with many accountable consultants who felt tremendous ownership for their client’s success. In fact, some of the most outstanding consultants I have worked with were “in the fire” with me in the most demanding environments. They require brains, heart, and guts to survive and a true sense of ownership and purpose to thrive. Have you had similar experiences with consultants who went above and beyond? Share your thoughts in the comments! #biotech #consultants #accountability #success

Biotech companies are competing for the attention of potential partners to fund their R&D and help them achieve commercial success. This BIO roundup article highlights key advice on decision-making: https://ow.ly/FZOM50StSSK.

If I woke up tomorrow and had to rethink biotech process development and scale-up. Here’s what I’d do: create a systematic, step-by-step plan to ensure that I assessed all critical aspects well before even considering the scale-up aspects for clinical production. People who embark on the same journey: - Are confused - Don’t know where to start - Feel overwhelmed The key is to remove the complexity out of the whole process development project. Once I changed my approach to creating a solid roadmap, I immediately: - Got peace of mind - Felt confident - Enjoyed the whole endeavor Biotech scientists succeeding process development and scale-up: - Prepare early - Know the ins and outs of their process - Leverage collaboration #cellculture #processdevelopment #bioprocessing #celltherapymanufacturing #cellandgenetherapy #leadbiotech

My 6 key takeaways : 1. Peak M&A Activity in 2019: The biotechnology sector experienced a record level of M&A activity in 2019. Following this peak, the sector saw an increase in valuations and broadened access to capital, leading to a cooling in deal-making activities. The emergence of high interest rates rendered inexpensive financing a thing of the past, causing M&A activity to stagnate. However, a noticeable acceleration in deal-making was observed in the fourth quarter of 2023. 2.Trend Continuation into 2024: The year 2024 witnessed a continuation of M&A activities, characterized by smaller transactions. Pharmaceutical companies were keen on acquiring clinical-stage assets to enhance their pipelines, adhering to the principle that compelling data drives favorable deals. 3. Challenges in Advancing to Late-Stage Development: Companies aiming to progress assets to Phase III and commercialization faced challenges in securing funding. Investor focus has shifted towards seeking returns and successful exits, which aligns with the commercialization expertise of large pharmaceutical companies. 4. Inflation and Interest Rate Trends: Signs of inflation stabilizing, accompanied by a decrease in interest rates, suggest a potential resurgence of interest in biotech initial public offerings (IPOs). However, this remains speculative at this stage. 5. Significance of Phase II Data: Data from Phase II trials has emerged as a crucial factor in de-risking deal-making activities, representing a key milestone for attracting investment and partnership interest. 6.Venture Capital Trends: The venture capital landscape reached a low in 2023, with a noted decrease in IPO activities prompting investors to reassess the duration of their support for portfolio companies. This period of introspection was driven by a lack of exit opportunities, impacting the willingness of investors to sustain long-term investments. #celltherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #pharmaceuticals #lifesciences #healthcare #dealmaking #investment #funding #financing #publicofferings #BiotechMnA #mergersandacquisitions #PharmaDeals2024 #ClinicalStageInvestment #BiotechFundingChallenges #commercialization . #InflationAndBiotech #PhaseIIData #VentureCapitalTrends #BiotechIPOs #InvestorReturns #DealmakingDeRisk #biotechnology #M&A #Pharma #Investors #IPOs #ClinicalStage #Data #Commercialization #VentureCapital #clinicaltrials

Register for our upcoming webinar!

In our summer #lifesciences outlook, we examine: 👉 Funding concerns for #biotechs 👉 Impacts of new #medtech regulations 👉 The resilience of life sciences companies https://rsm.us/3KVZLmO

Wondering how to make the transition from research to process development seamless? These are the secrets!